We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Watson is Second Drugmaker to Pull Generic Wellbutrin
Watson is Second Drugmaker to Pull Generic Wellbutrin
October 18, 2013
Watson is withdrawing from the market its 300 mg extended release (ER) version of bupropion hydrochloride (HCl) after updated bioequivalence studies showed the drug is not therapeutically equivalent to its brand counterpart, Wellbutrin XL 300 mg.